China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the "Group") is a leading China-based pharmaceutical services company with the largest third-party promotion network in China in terms of hospital coverage, therapeutic focus and number of salespeople. The Group was established in 1995, and was listed on AIM in London (ticker: CMSH) in June 2007,and was listed on Main Board Market in Hong Kong on 28th September 2010. while was delisted at AIM at the same time.
CMS has the largest third-party promotion network in China in terms of hospital coverage, therapeutic focus and number of salespeople. With over 950 staff in its marketing, promotion and sales team, CMS reaches close to 6,000 hospitals located across 30 provinces in China. As a leading China-based pharmaceutical services company, CMS introduces drugs that prove to be competitive and focuses on providing marketing, promotion and sales services to specialty pharmaceutical companies by leveraging its successful product selection system and its insights in China’s pharmaceutical market.
CMS follows a market-oriented product selection strategy and introduces prescription drugs with high growth potential. CMS formulates appropriate marketing strategies for each drug, leveraging its insights in the prevailing treatment protocols of physicians and the demographic profile of the relevant patient pool in China, and competitive advantages of drugs.
To help drive demand for pharmaceutical products and promote the products to end-users, the Company’s professional, stable and experienced marketing, promotion and sales team conducts physician-oriented academic promotion activities such as one-on-one physician visits, medical symposia and industry conferences. With its proprietary information management system, CMS is also able to keep track of its marketing, promotion and sales activities, and review its operations in a timely manner, enabling the Company to manage its overall business effectively and efficiently.
but also extend and cover its business scope to include the central nervous system (or CNS), hepatology, gastroenterology, infectious diseases, urology, ophthalmology, cardiovascular disease, pediatrics and oncology.
In addition, CMS also provides other ancillary services needed by pharmaceutical companies to introduce their products to China, including handling product registration, clinical trials, and bidding in collective tender processes. The extensive distribution network comprising around 300 distributors helps the Company dispatch drugs to hospitals on a timely basis.
CMS’s product positioning, strategic planning, efficient execution and project management have contributed to the remarkable performance of the Company. For the three years from 2007 to 2009, the Company was able to sustain a compound annual growth rate (CAGR) of 36.5% in total revenue. The Company has received a number of recognitions – it was included in Forbe list of “Asia’s Best 200 Enterprises Under a Billion” in 2008, named one of the “Top 100 Enterprises in Shenzhen”, and made the 2010 Forbes list of “China’s Best Up-and-Coming Business”.
As a leading China-based pharmaceutical services company, CMS will continue to strengthen its leading position by expanding its product portfolio and marketing, promotion and sales network. With its professional services, CMS will tap in the enormous growth potential of the Chinese pharmaceutical market and strives to become the preferred partner of foreign pharmaceutical companies targeting the China market.
